Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

被引：0
|
作者：
Florence Lerebours
Marina Pulido
Emmanuelle Fourme
Marc Debled
Véronique Becette
Hervé Bonnefoi
Sofia Rivera
Gaetan MacGrogan
Marie-Ange Mouret-Reynier
Christine Tunon de Lara
Jean-Yves Pierga
Christel Breton-Callu
Laurence Venat-Bouvet
Simone Mathoulin-Pélissier
Thibault de la Motte rouge
Florence Dalenc
Brigitte Sigal
Thomas Bachelot
Jérôme Lemonnier
Nathalie Quenel-Tueux
机构：
[1] Institut Curie,Department of Radiation Oncology
[2] Clinical and Epidemiological Research Unit,undefined
[3] Institut Bergonié,undefined
[4] INSERM CIC 14.01,undefined
[5] Institut Bergonié,undefined
[6] Institut Curie,undefined
[7] Gustave Roussy Cancer Campus,undefined
[8] Centre Jean Perrin,undefined
[9] CHU,undefined
[10] Centre Eugène Marquis,undefined
[11] Institut Claudius Regaud-IUCT Oncopole,undefined
[12] Centre Léon Bérard,undefined
[13] R&D UNICANCER,undefined
[14] UCBG,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 765
页数：6
相关论文
共 50 条
  • [1] Predictive factors of 5-year relapse-free survival in HR+/HER2-breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
    Lerebours, Florence
    Pulido, Marina
    Fourme, Emmanuelle
    Debled, Marc
    Becette, Veronique
    Bonnefoi, Herve
    Rivera, Sofia
    MacGrogan, Gaetan
    Mouret-Reynier, Marie-Ange
    de Lara, Christine Tunon
    Pierga, Jean-Yves
    Breton-Callu, Christel
    Venat-Bouvet, Laurence
    Mathoulin-Pelissier, Simone
    de la Motte rouge, Thibault
    Dalenc, Florence
    Sigal, Brigitte
    Bachelot, Thomas
    Lemonnier, Jerome
    Quenel-Tueux, Nathalie
    BRITISH JOURNAL OF CANCER, 2020, 122 (06) : 759 - 765
  • [2] 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials
    Lerebours, F.
    Pulido, M.
    Fourme, E.
    Debled, M.
    Becette, V.
    Bonnefoi, H.
    Rivera, S.
    Mac Grogan, G.
    Mouret-Reynier, M. A.
    de Lara, C. Tunon
    Pierga, J. Y.
    Breton-Callu, C.
    Venat-Bouvet, L.
    Mathoulin-Pelissier, S.
    Kerbrat, P.
    Dalenc, F.
    Sigal, B.
    Bachelot, T.
    Lemonnier, J.
    Lerebours
    Quenel-Tueux, N.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S19 - S19
  • [3] Mamographic density and disease-free survival in [HR+, HER2-] locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Ingrid Rojas, Katerin
    Flores, Raymundo
    Flores, Claudio J.
    Pinto, Joseph A.
    Leonidas Gomez, Henry
    Castaneda, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [5] Addition of Ribociclib to Endocrine Therapy Improves Outcomes in EarlyStage, HR+/HER2- Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 352 - 352
  • [6] Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
    Valerio, Maria Rosaria
    Martorana, Federica
    Sano, Maria Vita
    Sambataro, Daniela
    Motta, Gianmarco
    Motta, Lucia
    Pavone, Giuliana
    Gebbia, Vittorio
    Scandurra, Giuseppa
    BIOMEDICINES, 2025, 13 (03)
  • [7] Clinicopathological and molecular features of HR+/HER2- breast cancer patients with distinct endocrine resistance patterns
    Zhang, Siwei
    Wang, Han
    Zhang, Hang
    Zhuang, Qingyuan
    Zhu, Xiaohui
    Xiao, Yi
    Jiang, Yizhou
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [8] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Mammographic density and disease-free survival in [HR+,HER2-] locally advanced breast cancer
    Rojas, K.
    Flores, R.
    Flores, C.
    Pinto, J.
    Gomez, H. L.
    Castaneda, C.
    BREAST, 2015, 24 : S103 - S103
  • [10] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E. P.
    Huang, C.
    Senkus-Konefka, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R. J.
    Andre, V.
    Munoz, M.
    Antonio, B. San
    Shahir, A.
    Jimenez, M. Martin
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
12345